> Details

Brunelli, Matteo; Tafuri, Alessandro; Cima, Luca; Cerruto, Maria Angela; Milella, Michele; Zivi, Andrea; Buti, Sebastiano; Bersanelli, Melissa; Fornarini, Giuseppe; Vellone, Valerio Gaetano; Rebuzzi, Sara Elena; Procopio, Giuseppe; Verzoni, Elena; Bracarda, Sergio; Sabbatini, Roberto; Baldessari, Cinzia; Eccher, Albino; Passalacqua, Rodolfo; Perrucci, Bruno; Giganti, Maria Olga; Donini, Maddalena; Panni, Stefano; Tucci, Marcello; Prati, Veronica; [...]

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma
  • Contributor: Brunelli, Matteo; Tafuri, Alessandro; Cima, Luca; Cerruto, Maria Angela; Milella, Michele; Zivi, Andrea; Buti, Sebastiano; Bersanelli, Melissa; Fornarini, Giuseppe; Vellone, Valerio Gaetano; Rebuzzi, Sara Elena; Procopio, Giuseppe; Verzoni, Elena; Bracarda, Sergio; Sabbatini, Roberto; Baldessari, Cinzia; Eccher, Albino; Passalacqua, Rodolfo; Perrucci, Bruno; Giganti, Maria Olga; Donini, Maddalena; Panni, Stefano; Tucci, Marcello; Prati, Veronica; [...]
  • Published: BMJ, 2022
  • Published in: Journal of Clinical Pathology, 75 (2022) 1, Seite 39-44
  • Language: English
  • DOI: 10.1136/jclinpath-2020-207089
  • ISSN: 0021-9746; 1472-4146
  • Origination:
  • Footnote:
  • Description: AimsAccording to The Cancer Genome Atlas (TCGA), around 9% of bladder carcinomas usually show abnormalities of the murine double minute 2 (MDM2) gene, but a few studies have been investigated them. We profiled MDM2 gene amplification in a series of urothelial carcinomas (UC) considering the molecular subtypes and expression of programmed death ligand 1 (PD-L1).Methods117 patients with muscle-invasive UC (pT2-3) without (N0) or with (N+) lymph-node metastases were revised. Only cases with availability of in toto specimens and follow-up were studied. Tissue microarray was built. p53, ER, RB1, GATA-3, CK20, CK5/6, CD44 and PD-L1 (clone sp263) immunoexpression was evaluated. Fluorescent in situ hybridisation was assessed by using the HER-2/neu, FGFR-3, CDKN2A and MDM2 probes. True (ratio 12q/CEP12 >2) MDM2 gene amplification was distinguished from polyploidy/gains (ratio <2, absolute copy number of MDM-2 >2). MDM2 and PD-L1 values were correlated to the TCGA molecular phenotypes. Statistical analysis was performed.Results6/50 (12%) cases (5 N0 and 1 N+) were amplified for MDM2 without matching to molecular phenotypes. Of 50, 14 (37%) cases expressed PD-L1 at 1% cut-off; 3/50 (9%) at >50% cut-off; of these, 2 cases on side of neoplasia among inflammatory cells. Only one out of six (17%) cases amplified for MDM2 showed expression (>50% cut-off) of PD-L1. MDM2 amplification was independent to all documented profiles (k test=0.3) and was prevalent in recurrent UC.ConclusionMDM2 amplification has been seen in both PD-L1 positive and negative muscle-invasive bladder UC independently from the TCGA molecular phenotypes. MDM2 and PD-L1 might be assessed in order to predict a better response to combo/single targeted therapies.